Liquidia Urges SCOTUS to Restore Preclusive Effect to PTAB Final Written Decisions
Last week, biopharmaceutical company Liquidia Technologies filed a petition for writ of certiorari with the U.S. Supreme Court to appeal a Federal Circuit ruling that affirmed induced infringement findings against Liquidia following the patent at issue being invalidated by the PTAB.
United States Us Court United Therapeutics Corporation Treprostinil Administration Us Food Drug Administration Hargis Industries
Source: ipwatchdog.com